Why Is Techne (TECH) Down 3% Since Last Earnings Report?
In This Article:
It has been about a month since the last earnings report for Techne (TECH). Shares have lost about 3% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Techne due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month.
The consensus estimate has shifted -6.64% due to these changes.
VGM Scores
At this time, Techne has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Techne has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Techne is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Astrazeneca (AZN), a stock from the same industry, has gained 7.5%. The company reported its results for the quarter ended March 2025 more than a month ago.
Astrazeneca reported revenues of $13.59 billion in the last reported quarter, representing a year-over-year change of +7.2%. EPS of $1.24 for the same period compares with $1.03 a year ago.
Advertisement: High Yield Savings Offers
For the current quarter, Astrazeneca is expected to post earnings of $1.11 per share, indicating a change of +12.1% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.5% over the last 30 days.
Astrazeneca has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bio-Techne Corp (TECH) : Free Stock Analysis Report
AstraZeneca PLC (AZN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).